Publications by authors named "S Tennant"

Objective: To provide primary care providers (PCPs) with an approach for diagnosing and managing endocervical polyps, detailing a procedural technique for cervical polypectomy and outlining key information on when to refer to a gynecologist.

Sources Of Information: This review and approach are based on the second author's clinical practice and available literature from 1994 to 2023.

Main Message: Cervical polyps are commonly asymptomatic and benign, but can cause intermenstrual and postcoital bleeding.

View Article and Find Full Text PDF

Background: Enteric fever caused by Salmonella enterica serovars Typhi and Paratyphi A in addition to gastroenteritis and invasive disease, predominantly attributable to nontyphoidal Salmonella serovars Typhimurium and Enteritidis, are major causes of death and disability across the globe. A broad-spectrum vaccine that protects against disease caused by typhoidal and nontyphoidal serovars of Salmonella is not available for humans but would prevent a considerable burden of disease worldwide.

Methods: We previously developed a broad-spectrum vaccine for Gram-negative bacteria that is based on the inner core domain of detoxified Escherichia coli O111, Rc (J5) mutant lipooligosaccharide, a highly conserved antigen across Gram-negative bacteria, complexed with an outer membrane protein of group B Neisseria meningitidis.

View Article and Find Full Text PDF
Article Synopsis
  • Serotype 6 is a common cause of moderate to severe diarrhea but remains understudied, prompting research into its genomic and phenotypic characteristics compared to other serotypes.
  • Genomic analyses revealed notable similarities among 6 strains across different regions and timeframes, along with the identification of a potential novel virulence factor and unique patterns of antibiotic susceptibility specific to geographic locations.
  • Findings suggest that serotype 6 has distinct genetic and phenotypic traits that could enhance vaccine development and diagnostic tools, which is crucial given the rising incidence of shigellosis, particularly in low- and middle-income countries.
View Article and Find Full Text PDF

is well recognized as a serious cause of infection in healthcare-associated settings and immunocompromised individuals; however, accumulating evidence from resource-limited nations documents an alarming rise in community-acquired . infections, manifesting as bacteremia and pneumonia as well as neonatal sepsis. The emergence of hypervirulent and antibiotic-resistant .

View Article and Find Full Text PDF
Article Synopsis
  • Bacterial gastrointestinal diseases, particularly those caused by various Shigella species, lead to significant health issues globally, causing approximately 125 million cases of shigellosis and 14,000 deaths each year, mostly in young children in developing nations.
  • A Phase 1 clinical trial evaluated the safety and tolerability of a new treatment called ShigActive™, a lytic bacteriophage aimed at Shigella, comparing its effects with a placebo over 29 days.
  • Results showed that ShigActive™ was generally safe and well tolerated, with mild side effects reported by some participants and no serious adverse events, indicating it could be a potential option for treating shigellosis
View Article and Find Full Text PDF